AbbVie Revenue 2010-2020 | ABBV

AbbVie annual/quarterly revenue history and growth rate from 2010 to 2020. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • AbbVie revenue for the quarter ending December 31, 2020 was $13.858B, a 59.21% increase year-over-year.
  • AbbVie revenue for the twelve months ending December 31, 2020 was $45.804B, a 37.69% increase year-over-year.
  • AbbVie annual revenue for 2020 was $45.804B, a 37.69% increase from 2019.
  • AbbVie annual revenue for 2019 was $33.266B, a 1.57% increase from 2018.
  • AbbVie annual revenue for 2018 was $32.753B, a 16.08% increase from 2017.
AbbVie Annual Revenue
(Millions of US $)
2020 $45,804
2019 $33,266
2018 $32,753
2017 $28,216
2016 $25,638
2015 $22,859
2014 $19,960
2013 $18,790
2012 $18,380
2011 $17,444
2010 $15,638
2009 $14,214
AbbVie Quarterly Revenue
(Millions of US $)
2020-12-31 $13,858
2020-09-30 $12,902
2020-06-30 $10,425
2020-03-31 $8,619
2019-12-31 $8,704
2019-09-30 $8,479
2019-06-30 $8,255
2019-03-31 $7,828
2018-12-31 $8,305
2018-09-30 $8,236
2018-06-30 $8,278
2018-03-31 $7,934
2017-12-31 $7,739
2017-09-30 $6,995
2017-06-30 $6,944
2017-03-31 $6,538
2016-12-31 $6,796
2016-09-30 $6,432
2016-06-30 $6,452
2016-03-31 $5,958
2015-12-31 $6,400
2015-09-30 $5,944
2015-06-30 $5,475
2015-03-31 $5,040
2014-12-31 $5,452
2014-09-30 $5,019
2014-06-30 $4,926
2014-03-31 $4,563
2013-12-31 $5,111
2013-09-30 $4,658
2013-06-30 $4,692
2013-03-31 $4,329
2012-12-31 $5,206
2012-09-30 $4,508
2012-06-30 $4,493
2012-03-31 $4,173
2011-12-31 $4,864
2011-09-30 $4,409
2011-06-30 $4,274
2011-03-31 $3,897
2010-12-31
2009-12-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $189.532B $45.804B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $427.844B 20.27
Roche Holding AG (RHHBY) Switzerland $277.912B 0.00
Novartis AG (NVS) Switzerland $198.453B 15.05
Eli Lilly (LLY) United States $195.346B 25.70
Merck (MRK) United States $188.791B 12.58
Pfizer (PFE) United States $187.985B 12.43
Novo Nordisk (NVO) Denmark $170.346B 26.31
AstraZeneca (AZN) United Kingdom $128.369B 24.21
Sanofi (SNY) $115.322B 13.67
GlaxoSmithKline (GSK) United Kingdom $86.243B 11.50
H Lundbeck (HLUYY) Denmark $7.787B 13.77
Innoviva (INVA) United States $1.178B 5.23